Publication of List of Manufacturers Revoked from Licensing for the Manufacture of Therapeutic Goods - Ludwig Institute for Cancer Research LTD and Mesoblast LTD

Overview

The Therapeutic Goods Act 1989, enacted by the Commonwealth Parliament, governs the regulation of therapeutic goods in Australia, aiming to ensure their quality, safety, and efficacy. One specific instance of its application is the revocation of a manufacturer's licence to produce therapeutic goods, as seen in the 20 February 2015 Gazette notice issued by the Therapeutic Goods Administration. This particular notice addresses the revocation of licences held by Ludwig Institute for Cancer Research Ltd and Mesoblast Ltd, both at the request of the manufacturers themselves. The act empowers the Secretary to revoke such licences under Section 41(1)(d), thereby maintaining stringent controls over the therapeutic goods market and upholding public health standards.

Scope and Application

The Therapeutic Goods Act 1989 applies to a wide range of therapeutic goods, encompassing medicines, medical devices, blood, and tissues, with a primary focus on ensuring the safety, quality, and efficacy of these goods within Australia. The Act regulates entities and persons involved in the manufacturing, importation, supply, and advertising of therapeutic goods. It applies to individuals, corporations, and institutions that are involved in any aspect of the therapeutic goods supply chain, from production to distribution and sale. The Act's jurisdictional reach extends across the Commonwealth of Australia, including all states and territories, establishing a uniform regulatory framework for therapeutic goods. Exclusions and exemptions may apply, such as for certain research activities or specific classes of goods that are subject to separate regulations or exemptions under the Act. Additionally, the application and enforcement of the Act can be extended or restricted through subordinate instruments, which may include regulations or guidelines issued by the Therapeutic Goods Administration. These instruments provide detailed operational requirements and procedural standards that complement the primary legislation.

Key Provisions

The Therapeutic Goods Act 1989 (the "Act") contains various provisions governing the manufacture, supply, and distribution of therapeutic goods in Australia. Specifically, section 41(1)(d) (1) of the Act allows the Secretary to revoke a manufacturer's licence if certain conditions are met. In the notice published by Dr. Harry Rothenfluh, Delegate of the Secretary of the Department of Health, Therapeutic Goods Administration, the Secretary exercised this power by revoking the licences held by Ludwig Institute for Cancer Research Ltd and Mesoblast Ltd. These revocations were made at the request of the respective manufacturers. The Act imposes several obligations on entities holding a licence to manufacture therapeutic goods. These include ensuring compliance with good manufacturing practices, maintaining records and documentation as required, and adhering to the conditions specified in their licences. Licence holders are also required to notify the Secretary of any changes to their business operations or manufacturing practices that could impact the safety and efficacy of the therapeutic goods they produce. The revocation of a licence signifies that the manufacturer is no longer authorised to produce therapeutic goods and must cease all manufacturing activities immediately. Failure to comply with the requirements of the Act, including the terms and conditions of a manufacturing licence, can result in enforcement actions. In cases of serious non-compliance, the Secretary may revoke a licence under section 41(1)(d) (2). This can lead to a cessation of manufacturing activities and potential legal consequences for the manufacturer. Furthermore, any individual or entity found to have contravened the Act may be subject to penalties under the Act or other relevant legislation. For instance, under section 87 (3) of the Act, a person who contravenes certain provisions may be liable to a fine of up to $220,000 for a corporation and $44,000 for an individual, along with potential criminal prosecution. These penalties underscore the importance of adhering to the regulatory requirements set forth in the Act.